DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 8, 2004; DOI: 10.1124/dmd.104.001099


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.001099v1
32/12/1337    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krueger, S. K
Right arrow Articles by Williams, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krueger, S. K
Right arrow Articles by Williams, D. E.


Received for publication June 22, 2004.
Revised August 26, 2004.
Accepted for publication September 7, 2004.

Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent

Sharon K Krueger 1, Lisbeth K Siddens 1, Sarah R Martin 1, Zhen Yu 1, Clifford B Pereira 1, Erwin T Cabacungan 2, Ronald N Hines 2, Kristin G Ardlie 3, Judy L Raucy 4, David E. Williams 1*

1 Oregon State University 2 Medical College of Wisconsin 3 Genomics Collaborative, Inc. 4 California Toxicology Research Institute

* Address correspondence to: E-mail: david.williams{at}orst.edu

Abstract

A polymorphism for the phase I drug metabolizing enzyme, flavin-containing monooxygenase isoform 2 (FMO2), encoding either truncated inactive protein, FMO2X472 (FMO2.2A), or full-length active enzyme, FMO2Q472 (FMO2.1), is known and exhibits significant inter-ethnic differences in allelic frequency. FMO2 is the major or sole FMO isoform expressed in the lung of most mammals, including non-human primates. To date, FMO2.1 has been found only in African-American and Hispanic populations, rendering individuals with this allele subject to drug metabolism that is potentially different from that of the general population. Approximately 26% of African-Americans (N=180) possess the FMO2*1 allele. In preliminary studies, we initially estimated that 5% of Hispanics (N=40) have the FMO2*1 allele, but access to large cohorts of individuals of defined National origin has allowed us to determine the occurrence among Mexican-American and Puerto Rican-American groups. We used allele-specific genotyping to detect FMO2*1 from 632 Hispanic individuals, including 280 individuals of Mexican origin and 327 individuals of Puerto Rican origin. Statistical analysis indicated that results from Mexican (five sample sources) and Puerto Rican (three sample sources) samples were consistent with the hypothesis of homogeneity within each group from different sources. Data were subsequently pooled across sources to test for evidence of a difference in occurrence of FMO2*1 between ethnic groups. There was strong evidence (p=0.0066) that FMO2*1 is more common among Puerto Ricans (7%) than individuals of Mexican descent (2%). The overall occurrence of FMO2*1 among Hispanics of all origins is estimated to be between 2 and 7%.


Key words: ethnic differences, extrahepatic drug metabolism, flavin-containing monooxygenase, genetic polymorphism, human genetics, inhalation toxicology, pharmacogenetics, polymorphisms, pulmonary metabolism


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J. Zhang and J. R. Cashman
QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES
Drug Metab. Dispos., January 1, 2006; 34(1): 19 - 26.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.